BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3245759)

  • 1. Effective treatment of recurrent acromegaly with a long-active somatostatin analogue (sandostatin).
    Miranda R; Zárate A; Ruíz Velasco G
    Arch Invest Med (Mex); 1988; 19(4):445-8. PubMed ID: 3245759
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acromegaly associated with McCune-Albright syndrome].
    Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
    Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acromegaly and its treatment.
    Lamberts SW
    J Endocrinol; 1997 Oct; 155 Suppl 1():S49-51; discussion S67-71. PubMed ID: 9389995
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of long-term treatment with somatostatin analogue (SMS 201-995) on pituitary tumor shrinkage in acromegaly--report of two cases.
    Mukada K; Uozumi T; Takechi A; Arita K; Yano T; Hirohata T; Onda J; Ohta M
    Neurol Med Chir (Tokyo); 1992 Apr; 32(4):215-9. PubMed ID: 1378566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for dopamine agonists in the treatment of acromegaly.
    Jaquet P
    J Endocrinol; 1997 Oct; 155 Suppl 1():S59-60. PubMed ID: 9389998
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. Participants of the "Conference on Medical and Surgical Treatment of Pituitary Adenomas" (Zürich, 5th October, 1991).
    Fahlbusch R; Giovanelli M; Buchfelder M; Losa M
    J Endocrinol Invest; 1993 Jun; 16(6):449-60. PubMed ID: 8370920
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence supporting surgery as treatment of choice for acromegaly.
    Fahlbusch R; Honegger J; Buchfelder M
    J Endocrinol; 1997 Oct; 155 Suppl 1():S53-5. PubMed ID: 9389996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of therapy-resistant acromegaly using Sandostatin].
    von Werder K; Mehltretter G; Müller OA
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():29-31. PubMed ID: 1980775
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute liver injury and octreotide.
    González-Martín JA; Donnay S; Morillas J; Gómez-Aparicio C; Garcia-Cano J; Pérez-Vigara G; Roldán A
    Am J Gastroenterol; 1996 Nov; 91(11):2434-5. PubMed ID: 8931436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analgesic effect on headaches of octreotide, a somatostatin analogue, in a case of non-functioning pituitary adenoma].
    Turpin G; Foubert L; Noel-Wekstein S; Kujas M; De Gennes JL
    Presse Med; 1991 Dec; 20(43):2219-20. PubMed ID: 1838161
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presurgical octreotide treatment in acromegaly.
    Stevenaert A; Beckers A
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():18-20. PubMed ID: 8372606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acromegaly and its treatment in the McCune-Albright syndrome.
    Premawardhana LD; Vora JP; Mills R; Scanlon MF
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):605-8. PubMed ID: 1424186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in sella turcica volume. An effect of long-term treatment with the somatostatin analogue, SMS 201-995, in acromegalic patients.
    Lund E; Jørgensen J; Christensen SE; Weeke J; Orskov H; Harris AG
    Neuroradiology; 1991; 33(2):162-4. PubMed ID: 2046904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.